on January 2, 2008
Published online before print January 2, 2008, doi: 10.1161/HYPERTENSIONAHA.107.102467
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 5, 2007
From the Departments of Internal Medicine (A.W.-C., J.H., R.N., S.A.C., P.R.K., M.R.H., N.R., V.G.D., B.T.A., Y.W., J.R.S.) and Medical Pharmacology and Physiology (J.R.S.) and the Diabetes and Cardiovascular Laboratory (A.W.-C., J.H., R.N., S.A.C., P.R.K., M.R.H., N.R., V.G.D., B.T.A., Y.W., J.R.S.), University of Missouri School of Medicine, Columbia; the Harry S. Truman Veterans’ Affairs Medical Center (A.W.-C., J.R.S.), Columbia, Mo; and the School of Medicine (C.F.), Wake Forest University, Winston-Salem, NC. * To whom correspondence should be addressed. E-mail: whaleyconnella{at}health.missouri.edu.
Abstract—Activation of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase by angiotensin II is integral to the formation of oxidative stress in the vasculature and the kidney. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibition is associated with reductions of oxidative stress in the vasculature and kidney and associated decreases in albuminuria. Effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition on oxidative stress in the kidney and filtration barrier integrity are poorly understood. To investigate, we used transgenic TG(mRen2)27 (Ren2) rats, which harbor the mouse renin transgene and renin-angiotensin system activation, and an immortalized murine podocyte cell line. We treated young, male Ren2 and Sprague-Dawley rats with rosuvastatin (20 mg/kg IP) or placebo for 21 days. Compared with controls, we observed increases in systolic blood pressure, albuminuria, renal NADPH oxidase activity, and 3-nitrotryosine staining, with reductions in the rosuvastatin-treated Ren2. Structural changes on light and transmission electron microscopy, consistent with periarteriolar fibrosis and podocyte foot-process effacement, were attenuated with statin treatment. Nephrin expression was diminished in the Ren2 kidney and trended to normalize with statin treatment. Angiotensin II–dependent increases in podocyte NADPH oxidase activity and subunit expression (NOX2, NOX4, Rac, and p22phox) and reactive oxygen species generation were decreased after in vitro statin treatment. These data support a role for increased NADPH oxidase activity and subunit expression with resultant reactive oxygen species formation in the kidney and podocyte. Furthermore, statin attenuation of NADPH oxidase activation and reactive oxygen species formation in the kidney/podocyte seems to play roles in the abrogation of oxidative stress-induced filtration barrier injury and consequent albuminuria.
Revised on October 22, 2007
Attenuation of Reduced Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment
Adam Whaley-Connell*;
Key words: angiotensin II • albuminuria • glomerular filtration barrier • transgenic Ren2 rat • rosuvastatin
This article has been cited by other articles:
 |
|
 |
|
  V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario, et al. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H1128 - H1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Whaley-Connell, J. Habibi, Y. Wei, A. Gutweiler, J. Jellison, C. E. Wiedmeyer, C. M. Ferrario, and J. R. Sowers Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1013 - F1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Cormack-Aboud, P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol. Dial. Transplant., February 1, 2009; 24(2): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schmid, H. Stopper, F. Schweda, N. Queisser, and N. Schupp Angiotensin II Induces DNA Damage in the Kidney Cancer Res., November 15, 2008; 68(22): 9239 - 9246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf An Overview of the Extra-Lipid Effects of Rosuvastatin Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Lastra, A. Whaley-Connell, C. Manrique, J. Habibi, A. A. Gutweiler, L. Appesh, M. R. Hayden, Y. Wei, C. Ferrario, and J. R. Sowers Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E110 - E116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Zhou, I. H. Schuman, E. A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability Am J Physiol Renal Physiol, July 1, 2008; 295(1): F53 - F59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Welch Angiotensin II-Dependent Superoxide: Effects on Hypertension and Vascular Dysfunction Hypertension, July 1, 2008; 52(1): 51 - 56. [Full Text] [PDF]
|
|
|
|
|
|
K. B. Brosnihan, P. Li, J. P. Figueroa, D. Ganten, and C. M. Ferrario Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H1995 - H2001. [Abstract] [Full Text] [PDF]
|
|